Related Experiment Videos
Disease management of Prader-Willi syndrome
1Mattel Children's Hospital at UCLA, 10833 Le Conte Avenue, Room MDCC 22-315, Los Angeles, CA 90095-1752, USA. philliplee@mednet.ucla.edu
Insights
Prader-Willi Syndrome (PWS) is a genetic disorder characterized by severe hypotonia and insatiable appetite. Growth hormone treatment is essential for improving growth, muscle mass, bone density, and physical performance in children with PWS.
Area of Science:
- Genetics
- Endocrinology
- Pediatrics
Background:
- Prader-Willi Syndrome (PWS) is a rare genetic disorder affecting approximately 1 in 10,000 to 25,000 individuals.
- Key features include hypotonia, hyperphagia, short stature, and developmental issues.
- PWS is linked to deficiencies in growth hormone, impacting overall development.
Purpose of the Study:
- To review the role and efficacy of growth hormone (GH) treatment in managing Prader-Willi Syndrome.
- To highlight GH as a crucial component of comprehensive PWS care.
- To discuss ongoing research into GH therapy for PWS.
Main Methods:
- Literature review of studies on PWS and growth hormone treatment.
- Analysis of clinical trial data regarding GH efficacy in PWS patients.
- Examination of regulatory approvals for GH in PWS treatment.
Main Results:
- Growth hormone treatment significantly improves linear growth in children with PWS.
- GH therapy enhances muscle mass, bone mineral density, and physical performance.
- GH is the first and only pharmaceutical approved for childhood PWS in the US and Europe.
Conclusions:
- Growth hormone is an indispensable therapy for improving outcomes in Prader-Willi Syndrome.
- Continued research is vital to optimize GH dosage and understand long-term effects.
- Comprehensive care including GH treatment is essential for individuals with PWS across all age groups.
Abstract:
Prader-Willi Syndrome (PWS), first described in 1956, is a unique genetic condition with a prevalence of 1 in 10,000 - 25,000. Features include severe lifelong hypotonia, insatiable appetite, short stature, obsessive-compulsive behaviour, morbid obesity, hypogonadism, kyphosis, scoliosis and osteoporosis. Studies beginning in the 1970s demonstrated that PWS is associated with a deficiency in growth hormone. Growth hormone treatment in children with PWS improves linear growth and more importantly leads to an increased muscle mass, bone mineral density and physical performance. In mid-2000, growth hormone became the first pharmaceutical approved in the US and Europe for the treatment of childhood PWS. It is now considered an essential part of comprehensive care for this condition. Ongoing studies address issues of growth hormone dosage, long-term efficacy, effects on neonatal and childhood growth and development and effects in adults with PWS.